269 related articles for article (PubMed ID: 31358587)
1. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
[TBL] [Abstract][Full Text] [Related]
2. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
4. Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach.
Willeman T; Tonini J; Garnaud C; Bailly S; Gandia P; Stanke-Labesque F; Maubon D; Gautier-Veyret E
Fundam Clin Pharmacol; 2020 Apr; 34(2):279-287. PubMed ID: 31505058
[TBL] [Abstract][Full Text] [Related]
5. Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus.
Chanoine S; Gautier-Veyret E; Pluchart H; Tonini J; Fonrose X; Claustre J; Bedouch P; Stanke-Labesque F
Br J Clin Pharmacol; 2021 Feb; 87(2):427-435. PubMed ID: 32472569
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
[TBL] [Abstract][Full Text] [Related]
7. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.
Cojutti PG; Candoni A; Lazzarotto D; Rabassi N; Fanin R; Hope W; Pea F
Br J Clin Pharmacol; 2018 Nov; 84(11):2544-2550. PubMed ID: 29975796
[TBL] [Abstract][Full Text] [Related]
8. Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Cumpston A; Caddell R; Shillingburg A; Lu X; Wen S; Hamadani M; Craig M; Kanate AS
Antimicrob Agents Chemother; 2015 Aug; 59(8):4424-8. PubMed ID: 25987632
[TBL] [Abstract][Full Text] [Related]
9. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.
Launay M; Roux A; Beaumont L; Douvry B; Lecuyer L; Douez E; Picard C; Grenet D; Jullien V; Boussaud V; Guillemain R; Billaud EM
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311077
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.
Döring M; Cabanillas Stanchi KM; Queudeville M; Feucht J; Blaeschke F; Schlegel P; Feuchtinger T; Lang P; Müller I; Handgretinger R; Heinz WJ
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1281-1292. PubMed ID: 28258343
[TBL] [Abstract][Full Text] [Related]
13. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
Boglione-Kerrien C; Picard S; Tron C; Nimubona S; Gangneux JP; Lalanne S; Lemaitre F; Bellissant E; Verdier MC; Petitcollin A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):127-134. PubMed ID: 28932906
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
17. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Miceli MH; Perissinotti AJ; Kauffman CA; Couriel DR
Mycoses; 2015 Jul; 58(7):432-6. PubMed ID: 26102575
[TBL] [Abstract][Full Text] [Related]
18. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
[TBL] [Abstract][Full Text] [Related]
19. Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.
Leclerc E; Combarel D; Uzunov M; Leblond V; Funck-Brentano C; Zahr N
Sci Rep; 2018 Jan; 8(1):1681. PubMed ID: 29374234
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
